Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)

Abstract

Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

1 .- 83 . (canceled) 
     
     
         84 . A conjugate comprising a cytotoxic agent and an antibody that binds to human colony stimulating factor 1 receptor (CSF1R); wherein the antibody comprises a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO:15, an HC CDR2 having the sequence of SEQ ID NO:16, and an HC CDR3 having the sequence of SEQ ID NO:17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO:18, a LC CDR2 having the sequence of SEQ ID NO:19, and a LC CDR3 having the sequence of SEQ ID NO:20. 
     
     
         85 . The conjugate of  claim 84 , wherein the cytotoxic agent is a radioisotope, toxin, or chemotherapy agent. 
     
     
         86 . The conjugate of  claim 84 , wherein the cytotoxic agent is a chemotherapy agent. 
     
     
         87 . The conjugate of  claim 84 , wherein the conjugate further comprises a label. 
     
     
         88 . A conjugate comprising a label and an antibody that binds to human colony stimulating factor 1 receptor (CSF1R); wherein the antibody comprises a heavy chain comprising a heavy chain (HC) CDR1 having the sequence of SEQ ID NO:15, an HC CDR2 having the sequence of SEQ ID NO:16, and an HC CDR3 having the sequence of SEQ ID NO:17, and a light chain comprising a light chain (LC) CDR1 having the sequence of SEQ ID NO:18, a LC CDR2 having the sequence of SEQ ID NO:19, and a LC CDR3 having the sequence of SEQ ID NO:20. 
     
     
         89 . The conjugate of  claim 88 , wherein the label facilitates detection of the antibody. 
     
     
         90 . The conjugate of  claim 88 , wherein the label facilitates detection of human CSF1R. 
     
     
         91 . The conjugate of  claim 88 , wherein the label is a radioisotope, fluorescent group, enzymatic group, chemiluminescent group, biotin, epitope tag, or metal-binding tag. 
     
     
         92 . The conjugate of  claim 84 , wherein the antibody blocks binding of human colony stimulating factor 1 (CSF-1) and human interleukin 34 (IL-34) to human CSF1R. 
     
     
         93 . The conjugate of  claim 84 , wherein the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 39 and wherein the antibody light chain comprises the amino acid sequence of SEQ ID NO: 46. 
     
     
         94 . The conjugate of  claim 84 , wherein the antibody is an antigen binding fragment. 
     
     
         95 . The conjugate of  claim 94 , wherein the antibody is a Fab, an Fv, an scFv, a Fab′, or a (Fab′)2. 
     
     
         96 . The conjugate of  claim 84 , wherein the antibody is an IgG. 
     
     
         97 . The conjugate of  claim 84 , wherein the antibody is an IgG4 comprising an S241P mutation in at least one IgG4 heavy chain constant region. 
     
     
         98 . The conjugate of  claim 84 , wherein the antibody comprises a full length heavy chain and/or a full length light chain. 
     
     
         99 . The conjugate of  claim 93 , wherein the antibody is an antigen binding fragment. 
     
     
         100 . The conjugate of  claim 99 , wherein the antibody is a Fab, an Fv, an scFv, a Fab′, or a (Fab′)2. 
     
     
         101 . The conjugate of  claim 93 , wherein the antibody is an IgG. 
     
     
         102 . The conjugate of  claim 93 , wherein the antibody is an IgG4 comprising an S241P mutation in at least one IgG4 heavy chain constant region. 
     
     
         103 . The conjugate of  claim 93 , wherein the antibody comprises a full length heavy chain and/or a full length light chain. 
     
     
         104 . The conjugate of  claim 84 , wherein the antibody heavy chain comprises the amino acid sequence of SEQ ID NO: 53 and wherein the antibody light chain comprises the amino acid sequence of SEQ ID NO: 60. 
     
     
         105 . A pharmaceutical composition comprising the conjugate of  claim 84  and at least one pharmaceutically acceptable carrier.